Prodrugs built as multiple self-elimination-release spacers

• US 7,705,045 B2
• Filed: 11/14/2003
• Issued: 04/27/2010
• Est. Priority Date: 11/14/2002
• Status: Expired due to Fees

• Current Assignee: Syntarga BV (Synthon International Holding BV)
• Original Assignee: Syntarga BV (Synthon International Holding BV)
• Inventors: De Groot, Franciscus Marinus Hendrikus, Beusker, Patrick Henry, Scheeren, Johannes Wilhelm
• Primary Examiner(s): Kosack; Joseph R
• Application Number:
  US10/534,777
• Publication Number:
  US 20060116422A1
• Time in Patent Office: 2,356 Days
• Field of Search: 514/483, 560/25
• US Class Current: 514/483
• CPC Class Codes: A61K 47/555 pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
• CPC Class Codes: A61K 47/65 Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• CPC Class Codes: A61K 47/67 Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
• CPC Class Codes: A61K 47/6899 Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07C 271/28 to a carbon atom of a non-condensed six-membered aromatic ring
• CPC Class Codes: C07K 5/0806 the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Abstract

This invention concerns multiple release spacers and spacer systems, which release multiple leaving groups following a single activation. It concerns compounds comprising a specifier linked to two or more of the same or different leaving groups (L in the figure) via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release at least two leaving groups.

Claims

1. A compound having a formula selected from

V—

(W—

)_w(X—

)C((A—

)_aZ)_c,

V—

(W—

)_w(X—

)C(D((A—

)_aZ)_d)_c,

V—

(W—

)_w(X—

)C(D(E((A—

)_aZ)_e)_d)_c, and

V—

(W—

)_w(X—

)C(D(E(F((A—

)_aZ)_f)_e)_d)_c,

wherein;

V is an enzymatically removable specifier comprising an optionally protected peptide, which is optionally removable after binding to a receptor, or

taken together, V—

B is an oxidized form of B, wherein B is part of W or X;

each of W and X independently is a single release 1, (4+2n) electronic cascade spacer and has the formula;

2. The compound according to claim 1, wherein the Z groups are linked to the self-eliminating multiple release spacer or spacer system via an O, S, or aromatic N of the Z group.

3. The compound according to claim 1, wherein the Z groups are linked to the self-eliminating multiple release spacer or spacer system via an aliphatic N and wherein at least one multiple release spacer or spacer system of either generation C, D (if present), E (if present), or F (if present) is a phenol- or thiophenol-based multiple release spacer or spacer system, meaning that

i) B═

O or S for at least one multiple release spacer in said generation, or

ii) when B═

N for all multiple release spacers in said generation, at least one single release spacer is connected to at least two branches of at least one multiple release spacer in said generation, and B═

O or S for at least two of said single release spacers.

4. The compound according to claim 3, wherein B═

O or S for all multiple release spacers or spacer systems in said generation.

5. The compound according to claim 3, wherein the phenol- or thiophenol-based multiple release spacers are connected to either A or Z.

6. The compound according to claim 1, wherein group A is present, and Z is coupled via its hydroxyl group to A.

7. The compound of claim 1 wherein

(W—

)_w(X—

)C_c,

(W—

)_w(X—

)C(D_d)_c,

(W—

)_w(X—

)C(D(E_e)_d)_c or

(W—

)_w(X—

)C(D(E(F_f)_e)_d)_c

is selected from the group consisting of

8. The compound according to claim 7, the compound further comprising cyclization elimination spacers A.

9. The compound according to claim 1, wherein the specifier V contains a substrate that can be cleaved by plasmin, one of the cathepsins, cathepsin B, β

-glucuronidase, prostate-specific antigen (PSA), urokinase-type plasminogen activator (u-PA), a member of the family of matrix metalloproteinases, or wherein V-B is an oxidized form of B, or wherein V contains a nitro-(hetero)aromatic moiety that can be removed or transformed by reduction under hypoxic conditions or by reduction by a nitroreductase.

10. The compound according to claim 1, wherein Z is selected from an antibiotic, an anti-inflammatory agent, an anti-viral agent, and an anticancer agent.

11. The compound of claim 10, wherein Z is selected from (hydroxyl containing cytotoxic compounds) etoposide, combrestatin, camptothecin, irinotecan (CPT-11), SN-38, topotecan, 9-aminocamptothecin, 9-nitrocamptothecin, 10-hydroxycamptothecin, GG211, lurtotecan, paclitaxel, docetaxel, esperamycin, 1,8-dihydroxy-bicyclo[7.3.1]trideca-4-ene-2,6-diyne- 13-one, anguidine, doxorubicin, morpholine-doxorubicin, N-(5,5-diacetoxypentyl) doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, vincristine, vinblastine, tallysomycin, bleomycin, 4-bis(2-chloroethyl)aminophenol, 4-bis(2-fluoroethyl)aminophenol, and derivatives thereof,

(sulfhydryl containing compounds) esperamicin and 6-mercaptopurine, and derivatives thereof,

(carboxyl containing compounds) methotrexate, aminopterin, camptothecin (ring-opened form of the lactone), chlorambucil, melphalan, butyric acid and retinoic acid, and derivatives thereof, and

(aziridine amino containing or aromatic amino containing compounds) mitomycin C, mitomycin A, an anthracycline derivative containing an amine functionality with sufficient leaving group ability, mitoxantrone, 9-amino camptothecin, methotrexate, aminopterin, tallysomycin, bleomycin, actinomycin, N,N-bis(2-chloroethyl)-p-phenylenediamine, N,N-bis(2-fluoroethyl)-p-phenylenediamine, deoxycytidine, cytosine arabinoside, gemeitabine, and derivatives thereof, and

(aliphatic amino containing compounds) daunorubicin, doxorubicin, epirubicin, idarubicin, N-(5,5-diacetoxypentyl)doxorubicin, an anthracycline, N⁸-acetyl spermidine, 1-(2-chioroethyl)-1,2-dimethanesulfonyl hydrazine, or derivatives thereof.

12. The compound according to claim 11, wherein Z represents paclitaxel, docetaxel, or a derivative thereof, which is coupled to the self-eliminating multiple release spacer or spacer system via its 2′

-hydroxyl group.

13. The compound according to claim 11, wherein Z represents camptothecin, irinotecan (CPT-11), SN-38, topotecan, 9-aminocamptothecin, 9-nitrocamptothecin, 10-hydroxycamptothecin, GG211, lurtotecan, or a derivative thereof, which is coupled to the self-eliminating multiple release spacer or spacer system via its 20-hydroxyl group.

14. The compound according to claim 11, wherein Z represents SN-38, topotecan, 10-hydroxycamptothecin, etoposide, 4-bis(2-chloroethyl)aminophenol, 4-bis(2-fluoroethyl)aminophenol, or a derivative thereof, which is coupled to the self-eliminating multiple release spacer or spacer system via its phenolic hydroxyl group.

15. The compound according to claim 11, wherein Z represents 9-aminocamptothecin, N,N-bis(2-chloroethyl)-p-phenylenediamine, N,N-bis(2-fluoroethyl)-p-phenylenediamine, or a derivative thereof, which is coupled to the self-eliminating multiple release spacer or spacer system via its aromatic primary amine group.

16. The compound according to claim 11, wherein Z represents daunorubicin, doxorubicin, epirubicin, idarubicin, N-(5,5-diacetoxypentyl)doxorubicin, an anthracycline, N⁸-acetyl spermidine, 1-(2-chloroethyl)- 1,2-dimethanesulfonyl hydrazine, or derivatives thereof, which is coupled to the self-eliminating multiple release spacer or spacer system via its primary aliphatic amino group;

wherein

at least one multiple release spacer or spacer system of either generation C, D (if present), E (if present), or F (if present) is a phenol- or thiophenol-based multiple release spacer or spacer system, meaning that

i) B═

O or S for at least one multiple release spacer in said generation, or

ii) when B═

N for all multiple release spacers in said generation, at least one single release spacer is connected to at least two branches of at least one multiple release spacer in said generation, and B═

O or S for at least two of said single release spacers.

17. The compound according to claim 16, wherein B═

O or S for all multiple release spacers or spacer systems in said generation.

18. The compound according to claim 16, wherein the phenol- or thiophenol-based multiple release spacers are connected to either A or Z.

19. The compound according to claim 1, wherein the specifier V is a tripeptide.

20. The compound according to claim 19, wherein the tripeptide is linked via its C-terminus to the self-eliminating multiple release spacer or spacer system.

21. The compound of claim 20, wherein the C-terminal amino acid residue of the tripeptide is selected from arginine and lysine, the middle amino acid residue of the tripeptide is selected from alanine, valine, leucine, isoleucine, methionine, phenylalanine, cyclohexylglycine, tryptophan and proline, and the N-terminal amino acid residue of the tripeptide is selected from a D-amino acid residue and a protected L-amino acid residue including protected glycine.

22. The compound according to claim 21, wherein the specifier V is selected from D-alanylphenylalanyllysine, D-valylleucyllysine, D-alanylleucyllysine, D-valylphenylalanyllysine, D-valyltryptophanyllysine and D-alanyltryptophanyllysine.

23. The compound according to claim 1, wherein the specifier V is an amino-terminal capped peptide covalently linked via the C-terminus to the self-eliminating multiple release spacer or spacer system.

24. The compound according to claim 23, wherein the specifier V is selected from benzyloxycarbonylphenylalanyllysine, benzyloxycarbonylvalyllysine, D-phenylalanylphenylalanyllysine, benzyloxycarbonylvalylcitrulline, tert-butyl oxycarbonylphenylalanyllysine, benzyloxycarbonylalanylarginylarginine, benzyloxycarbonylphenylalanyl-N-tosylarginine, 2-aminoethylthiosuccinimidopropionylvalinylcitrulline, 2-aminoethylthiosuccinimidopropionyllysylphenylalanyllysine, acetylphenylalanyllysine, and benzyloxycarbonylphenylalanyl-O-benzoylthreonine.

25. The compound according to claim 1, wherein the specifier V comprises a reactive moiety that can be used to couple said compound to a targeting moiety.

26. The compound according to claim 25, wherein the reactive moiety is

27. The compound according to claim 25, wherein the reactive moiety is selected from an N-hydroxysuccinimide ester, a p-nitrophenyl ester, a pentafluorophenyl ester, an isothiocyanate, an isocyanate, an anhydride, an acid chloride, a sulfonyl chloride, and an aldehyde.

28. The compound according to claim 25, wherein the reactive moiety is a hydrazine group or an amino group.

29. The compound according to claim 1, wherein the specifier V comprises a targeting moiety.

30. The compound according to claim 29, wherein the targeting moiety is selected from the group consisting of a protein or protein fragment, an antibody or an antibody fragment, a receptor-binding or peptide vector moiety and a polymeric or dendritic moiety.

32. A diagnostic assay process, the process comprising:

incubating a sample comprising an enzyme with a compound according to claim 1 to cause enzymatic cleavage of the compound, and detecting one or more molecules liberated by the enzymatic cleavage.

33. The diagnostic assay process according to claim 32, wherein the detection of the one or more molecules determines the presence or amount of the enzyme.

34. The diagnostic assay process according to claim 33, wherein the detection of the one or more molecules determines the presence or amount of a protease.

35. The diagnostic assay process according to claim 34, wherein the compound that is used comprises a substrate for said protease and one or more Z groups are detected.

36. The diagnostic assay process according to claim 34, wherein the compound that is used comprises a substrate for the enzyme, which is the product of cleavage of its pro-enzyme precursor by said protease and one or more Z groups are detected.

37. A composite structure comprising two or more compounds according to claim 1 connected with a polymeric structure.

38. The compound according to claim 1, wherein the specifier V can be removed or transformed by an enzyme that is transported to the vicinity of or inside target cells or target tissue via ADEPT, PDEPT, MDEPT, VDEPT, or GDEPT.

39. A pharmaceutical composition comprising a compound according to claim 1.

40. A process for preparing a pharmaceutical composition comprising the step of mixing a compound according to claim 1 with a pharmaceutically acceptable carrier.

31. A compound selected from the group consisting of